药物更新:最近的药物批准,2026年冬季版
The Nurse practitioner
|January 22, 2026
概括
初级保健医生可以利用几种新的FDA批准的药物和疫苗在2025年初. 这些药物包括新型药物suzetrigine和gepotidacin,一种新的脑膜炎球菌疫苗,以及扩大了古塞尔库马布在克罗恩氏病中的适用性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 美国FDA不断批准新的治疗剂.
- 初级保健实践需要及时更新新药和疫苗.
- 新兴的治疗方法解决了各种医学领域的未满足需求.
研究的目的:
- 总结美国FDA从2025年上半年开始批准的关键药物和疫苗.
- 为初级保健从业者突出相关的药物.
- 通知临床医生关于新的治疗选择和适应症.
主要方法:
- 审查2025年上半年美国FDA批准数据.
- 确定具有初级保健相关性的药物和疫苗.
- 现有疗法新征兆的分类. 现有疗法的新征兆.
主要成果:
- 批准苏泽特里金 (Journavx) 和地波蒂达辛 (Blujepa) 的使用.
- 介绍了脑膜炎球菌A,B,C,W和Y群的疫苗 (Penmenvy).
- 新的批准包括clesrovimab-cfor (Enflonsia), acoltremon (Tryptyr),以及克罗恩病中的guselkumab (Tremfya) 的新指示.
结论:
- 一些重要的制药和生物产品在2025年初被FDA批准.
- 这些批准为初级保健和专业领域提供了新的治疗选择.
- 临床医生应该意识到患者护理的这些进步.
关键词:
克罗恩氏病 克罗恩氏病是什么?美国食品药品监督管理局 FDA FDA美国食品和药物管理局 (FDA) 批准剧烈的急性疼痛是一种疼痛.干眼疾病是干眼的疾病.脑膜炎是一种脑膜炎.新型药物 新型药物主要护理是一级医疗保健.呼吸道同胞性病毒尿路感染 尿路感染更多相关视频
相关概念视频
FDA Approved Drugs: Changes to Approved Drugs
247
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
247
Pharmacokinetics: Drug–Drug Interactions
389
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
389
Bioequivalence of Drugs: Drugs with Multiple Indications
154
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
154
Factors Influencing Drug Absorption: Drug Dissolution
1.1K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.1K
Factors Affecting Protein-Drug Binding: Drug-Related Factors
457
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
457
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
222
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
222


